R
Richard Lathe
Researcher at University of Edinburgh
Publications - 179
Citations - 20987
Richard Lathe is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Gene & Transgene. The author has an hindex of 52, co-authored 172 publications receiving 19962 citations. Previous affiliations of Richard Lathe include Centre national de la recherche scientifique & University of Strasbourg.
Papers
More filters
Patent
Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration
TL;DR: In this paper, a method for treating a patient in need of therapy for acute neuronal degeneration due to metabolic compromise of central or peripheral nervous system cells comprising administering to that patient a therapeutically effective amount of a 7α-hydroxy substituted steroid selected from 7αhydroxy-derivatives of estradiols, dehydroepiandrosterones and pregnenolones, and metabolic precursors thereof.
Journal ArticleDOI
Characterization of polyoma virus early proteins expressed from vaccinia virus recombinants
TL;DR: Evidence is presented that PyV early proteins expressed by the recombinants retain the biochemical characteristics of their authentic counterparts despite the cytopathic effect of VV infection.
Journal ArticleDOI
Reduced dementia incidence after varicella zoster vaccination in Wales 2013–2020
TL;DR: This study shows a clear association of shingles vaccination with reduced dementia, consistent with other observational cohort studies, and may reflect selection bias with people choosing to be vaccinated having a higher healthy life expectancy.
Journal ArticleDOI
Environmental Factors and Limbic Vulnerability in Childhood Autism
TL;DR: A two-hit combination of genetic susceptibility and environmental challenge is argued to underlie the rise in ASD.
Book ChapterDOI
New Generation of Rabies Vaccine
TL;DR: The Wistar Institute human diploid rabies vaccine, introduced in 1970, is now in general use in the United States and Western Europe and is too costly for extensive use in many of the developing countries, particularly those where rabies Vaccine is most needed.